Natural Alternatives International, Inc. Reports First Quarter 2026 Financial Results
Natural Alternatives International, Inc. (Nasdaq: NAII), known for its expertise in formulating and manufacturing customized nutritional supplements, has disclosed its financial performance for the first quarter of fiscal year 2026. The company reported a net loss of $0.3 million, equating to $0.05 per diluted share, on net sales amounting to $37.7 million. This marks an improvement compared to a net loss of $2.0 million, or $0.33 per diluted share, during the same period last year.
Revenue Growth and Private-Label Manufacturing
During the three months ending September 30, 2025, Natural Alternatives achieved a notable increase in net sales by $4.6 million, which is a 13.8% rise from the previous year’s comparable quarter. The private-label contract manufacturing segment experienced an even more substantial boost, climbing $5.4 million, or 17.7%. This uptick can be attributed to growing orders from existing clients as well as new customer acquisitions, demonstrating the efficacy of the company’s strategic sales initiatives.
Challenges in Royalty Revenues
Conversely, the company faced a decrease in revenues from CarnoSyn® beta-alanine royalty, licensing, and raw material sales, which dropped by 33.9% to $1.7 million, down from $2.5 million in the previous year. This reduction was largely influenced by decreased raw material orders from existing customers. However, it was somewhat offset by the successful launch of our new TriBsyn™ product and a rise in royalty and licensing revenues.
Improvements in Operational Income
In a positive turn, Natural Alternatives generated income from operations for Q1 of fiscal 2026, contrasting with a loss in the same period the prior year. This improvement is primarily driven by higher sales and enhanced gross profit, while selling, general, and administrative expenses remained relatively stable. The growth in gross profit can be attributed to better utilization of factory capacities and increased sales across both new and existing customers.
Financial Position and Future Outlook
As of September 30, 2025, Natural Alternatives reported cash reserves of $7.7 million and working capital of $31.2 million, compared to $12.3 million and $30.5 million from June 30, 2025. The company also enjoyed a borrowing capacity of $10.0 million on its credit facility, with only $2.5 million borrowed.
Leadership Insights
Mark A. Le Doux, Chairman and CEO of Natural Alternatives, recognized the significant improvement in sales and financial results, attributing this success to the dedication and hard work of their teams in nurturing current client relationships while also expanding their customer base. He expressed optimism about the company’s journey towards profitability in the latter half of fiscal year 2026. Le Doux further noted the surge in inventory levels indicates preparations for fulfilling current and anticipated future orders, highlighting the company’s strategic focus on sustainable profitability and innovative product adoption.
Strategic Product Focus and Market Positioning
One notable product highlighted during the announcement is TriBsyn™, designed to cater to consumers striving to maintain lean muscle mass and alleviate brain fog linked with medications like GLP-1 medications. The relevance of using supportive nutritional products for individuals dealing with obesity and diabetes is both timely and backed by clinical research, placing Natural Alternatives at the forefront of a healthcare revolution.
Supply Chain Management Efforts
Despite ongoing supply chain challenges, Natural Alternatives International is actively working to secure essential materials, gearing up for anticipated growth in sales and profitability as they progress through their fiscal year.
Frequently Asked Questions
What were Natural Alternatives International's Q1 sales figures?
The company reported net sales of $37.7 million for the first quarter of fiscal year 2026.
How does the recent financial performance compare to the previous year?
The company showed improvement, with a net loss of $0.3 million compared to a net loss of $2.0 million in the prior year.
What are the key drivers of revenue growth for the company?
Growth in sales stems from increased demand in the private-label contract manufacturing sector and higher orders from existing and new customers.
What strategic initiatives is the company focusing on for future profitability?
The company is concentrating on expanding client relationships and promoting its TriBsyn™ product for market growth.
What is the outlook for Natural Alternatives International in fiscal year 2026?
The company anticipates experiencing profitability in the second half of the fiscal year following strategic sales efforts and improved operational efficiency.
